Search results
Results from the WOW.Com Content Network
Viatris Pharmaceutical Plant in Istanbul. 27 may 2023. The company produces and sells a variety of medicines, with 1,400 approved therapeutic molecules in its portfolio. [ 31 ] It owns brands (like Viagra , Xanax , Lipitor ), [ 6 ] [ 32 ] generics , including branded and complex generics, biosimilars , [ 33 ] [ 34 ] and over-the-counter (OTC ...
“Pharma is a data-driven business,” explains Hussein Jaafar, a senior consultant at Lifescience Dynamics, who has largely led the charge on the team’s adoption of artificial intelligence.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
A financial forecast is an estimate of future financial outcomes for a company or project, usually applied in budgeting, capital budgeting and / or valuation. Depending on context, the term may also refer to listed company (quarterly) earnings guidance .
This was above analysts' estimate of $2.42 billion, according to Refinitiv data. The beat was driven by strong uptake of its top-selling drug Trikafta, which recorded sales of $2.24 billion in the ...
Schott Pharma (stylized as SCHOTT Pharma) is a provider of drug containment solutions and delivery systems for injectable drugs. [2] [3] Originally a division of glass manufacturer Schott AG, the company went public on the Frankfurt Stock Exchange in 2023. [4] Headquartered in Mainz, Germany, [5] [6] the company operates in 14 countries. [7]
"If we have efficacy data, we hope we'll have them any time from September onward," Dr. Mene Pangalos, executive vice president for AstraZeneca’s biopharmaceuticals research and development ...
[28] [29] IMS Health shareholders received 0.384 shares of Quintiles common stock for each share of IMS Health common stock they held, leaving the split of ownership at 51.4% IMS and 48.6% Quintiles. [30] [31] The merger was completed in October and the resulting company was a $17.6 billion company called QuintilesIMS. [9]